Page last updated: 2024-10-18

kynurenine and Colitis Gravis

kynurenine has been researched along with Colitis Gravis in 9 studies

Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.

Research Excerpts

ExcerptRelevanceReference
" Inflammation induces tryptophan metabolism along the kynurenine pathway (KP) and yields immunologically relevant metabolites."7.88Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis. ( Bissonnette, M; Ciorba, MA; Guillemin, GJ; Lim, CK; Meckel, K; Pekow, JR; Sofia, MA; Weber, CR, 2018)
" Inflammation induces tryptophan metabolism along the kynurenine pathway (KP) and yields immunologically relevant metabolites."3.88Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis. ( Bissonnette, M; Ciorba, MA; Guillemin, GJ; Lim, CK; Meckel, K; Pekow, JR; Sofia, MA; Weber, CR, 2018)
"C57Bl6 wild-type (control), IDO1-/-, Rag1-/-, and Rag1/IDO1 double-knockout mice were exposed to azoxymethane and dextran sodium sulfate to induce colitis and tumorigenesis."3.79IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. ( Bishnupuri, KS; Ciorba, MA; Foster, L; Kerr, TA; Marinshaw, JM; Newberry, RD; Rao, MS; Stenson, WF; Thaker, AI, 2013)
"Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) characterized by variable phenotypes."1.40Bimodal plasma metabolomics strategy identifies novel inflammatory metabolites in inflammatory bowel diseases. ( Bustamante, S; Campbell, B; Hejazi, L; Leong, RW; Pickford, R; Shin, S; Wasinger, VC; Yau, YY, 2014)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's5 (55.56)24.3611
2020's3 (33.33)2.80

Authors

AuthorsStudies
Lai, W1
Huang, Z1
Li, S2
Li, XG1
Luo, D1
Karpińska, G1
Dobrowolski, JC1
Yinda, CK1
Rector, A1
Zeller, M1
Conceição-Neto, N1
Heylen, E1
Maes, P1
Ghogomu, SM1
Van Ranst, M1
Matthijnssens, J1
Arthanari, SK1
Vanitha, J1
Ganesh, M1
Venkateshwaran, K1
de Lama Caro-Patón, G1
García-Salido, A1
Iglesias-Bouzas, MI1
Guillén, M1
Cañedo-Villaroya, E1
Martínez-Romera, I1
Serrano-González, A1
Casado-Flores, J1
Gale, P2
Chen, X2
Li, H1
Lucero-Prisno, DE1
Abdullah, AS1
Huang, J1
Laurence, C1
Liang, X1
Ma, Z1
Mao, Z1
Ren, R1
Wu, S1
Wang, N1
Wang, P2
Wang, T1
Yan, H1
Zou, Y1
Olsen, KM1
Gabler, NK1
Rademacher, CJ1
Schwartz, KJ1
Schweer, WP1
Gourley, GG1
Patience, JF1
Rauch, JC1
Stokes, RS1
Shike, DW1
Luebbe, KM1
Stalker, LA1
Klopfenstein, TJ1
Funston, RN1
Unger, PA1
Lighaam, LC1
Vermeulen, E1
Kruithof, S1
Makuch, M1
Culver, EL1
van Bruggen, R1
Remmerswaal, EBM1
Ten Berge, IJM1
Emmens, RW1
Niessen, HWM1
Barnes, E1
Wolbink, GJ1
van Ham, SM1
Rispens, T1
Liang, JX1
Lin, J1
Liu, J1
Wang, X1
Zhang, T1
Li, J1
Wu, Y2
Venier, M1
Salamova, A1
Gonçales, VR1
Lian, J1
Gautam, S1
Tilley, RD1
Gooding, JJ1
Kandel, YR1
Bradley, CA1
Chilvers, MI1
Mathew, FM1
Tenuta, AU1
Smith, DL1
Wise, KA1
Mueller, DS1
Lu, N1
Lu, M1
Liu, P1
Xu, H1
Qiu, X1
Hu, S1
Bai, S1
Wu, J1
Xue, S1
Dai, X1
Dharmage, SC1
Abramson, MJ1
Erbas, B1
Bennett, CM1
Svanes, C1
Hui, J1
Axelrad, C1
Lowe, AJ1
Lodge, CJ1
Hoshi, M1
Osawa, Y1
Nakamoto, K1
Morita, N1
Yamamoto, Y1
Ando, T1
Tashita, C1
Nabeshima, T1
Saito, K1
Gianesello, L1
Del Prete, D1
Ceol, M1
Priante, G1
Calò, LA1
Anglani, F1
Vekaria, HJ1
Hubbard, WB1
Scholpa, NE1
Spry, ML1
Gooch, JL1
Prince, SJ1
Schnellmann, RG1
Sullivan, PG1
Zhang, Q1
Hu, R1
Gu, Z1
Zhang, M1
Zhang, Z1
Peng, Y1
Feng, L1
Li, X4
Zhao, C1
Sarfaraz, K1
Gao, L1
Wang, H1
Wan, C1
Leng, J1
Yang, P1
Gao, X1
Gao, J1
Emam, HE1
Saad, NM1
Abdallah, AEM1
Ahmed, HB1
Palombo, M1
Ianus, A1
Guerreri, M1
Nunes, D1
Alexander, DC1
Shemesh, N1
Zhang, H1
Xiong, Q1
Liu, YS1
Hu, LX1
Shi, ZQ1
Ying, GG1
Chen, R1
Hong, X1
Yan, S1
Zha, J1
Gu, H1
Zhong, Q1
Zeng, Y1
Zhang, S1
Bu, Y1
Farghali, M1
Mayumi, M1
Syo, K1
Satoshi, A1
Seiichi, Y1
Takashima, S1
Ono, H1
Ap, Y1
Yamashiro, T1
Ahmed, MM1
Kotb, S1
Iwasaki, M1
Ihara, I1
Umetsu, K1
Hu, B1
Wang, Y2
Quan, J1
Huang, K1
Gu, X1
Zhu, J1
Yan, Y1
Wu, P1
Yang, L1
Zhao, J1
Koók, L1
Nemestóthy, N1
Bélafi-Bakó, K1
Bakonyi, P1
Luo, X1
Zhang, F1
Li, Q1
Xia, Q1
Li, Z1
Ye, W1
Ge, C1
Zakkula, A1
Pulipati, S1
Dittakavi, S1
Bestha, RM1
Zainuddin, M1
Trivedi, RK1
Mullangi, R1
Lo, GH1
Lin, CW1
Tai, CM1
Perng, DS1
Chen, IL1
Yeh, JH1
Lin, HC1
Rocha, GS1
Silva, MKL1
Cesarino, I1
Hazzaa, SM1
Abdelaziz, SAM1
Abd Eldaim, MA1
Abdel-Daim, MM1
Elgarawany, GE1
Larsson, P1
Ljuslinder, I1
Öhlund, D1
Myte, R1
Löfgren-Burström, A1
Zingmark, C1
Ling, A1
Edin, S1
Palmqvist, R1
Murthi, P1
Rajaraman, G1
Erwich, JJHM1
Dimitriadis, E1
Yoon, HG1
Oh, D1
Ahn, YC1
Noh, JM1
Pyo, H1
Cho, WK1
Song, YM1
Park, M1
Hwang, NY1
Sun, JM1
Kim, HK1
Zo, JI1
Shim, YM1
Persano, A1
Quaranta, F1
Taurino, A1
Siciliano, PA1
Iannacci, J1
Malekbala, MR1
Soltani, S1
Abdul Rashid, S1
Abdullah, LC1
Rashid, U1
Nehdi, IA1
Choong, TSY1
Teo, SH1
Xu, P1
Yan, F1
Zhao, Y1
Sun, S1
Ying, L1
Quinzi, V1
Caruso, S1
Mummolo, S1
Nota, A1
Angelone, AM1
Mattei, A1
Gatto, R1
Marzo, G1
Xin, W1
Severino, J1
Venkert, A1
Yu, H1
Knorr, D1
Yang, JM1
Carlson, L1
Hicks, R1
De Rosa, I1
Beckmann, NA1
Bitsch, RG1
Schonhoff, M1
Siebenrock, KA1
Schwarze, M1
Jaeger, S1
Manzella, CR1
Jayawardena, D1
Pagani, W1
Li, Y1
Alrefai, WA1
Bauer, J1
Jung, B1
Weber, CR2
Gill, RK1
Zhang, ZH1
Zabed, HM1
Yun, J1
Zhang, G1
Qi, X1
Sofia, MA1
Ciorba, MA2
Meckel, K1
Lim, CK1
Guillemin, GJ1
Bissonnette, M1
Pekow, JR1
Whiley, L1
Nye, LC1
Grant, I1
Andreas, N1
Chappell, KE1
Sarafian, MH1
Misra, R1
Plumb, RS1
Lewis, MR1
Nicholson, JK1
Holmes, E1
Swann, JR1
Wilson, ID1
Thaker, AI1
Rao, MS1
Bishnupuri, KS1
Kerr, TA1
Foster, L1
Marinshaw, JM1
Newberry, RD1
Stenson, WF1
Yau, YY1
Leong, RW1
Shin, S1
Bustamante, S1
Pickford, R1
Hejazi, L1
Campbell, B1
Wasinger, VC1
Forrest, CM1
Gould, SR1
Darlington, LG1
Stone, TW1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Kynurenine Pathway Metabolites as Novel Translational Biological Markers of Irritable Bowel Syndrome: Relationship to Gastrointestinal Function, Cognition and Co-morbid Depression[NCT01304355]85 participants (Anticipated)Observational2011-01-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for kynurenine and Colitis Gravis

ArticleYear
Kynurenine pathway metabolites modulated the comorbidity of IBD and depressive symptoms through the immune response.
    International immunopharmacology, 2023, Volume: 117

    Topics: Colitis, Ulcerative; Comorbidity; Depression; Humans; Inflammation; Kynurenine; Tryptophan

2023
    Computational & theoretical chemistry, 2013, Feb-01, Volume: 1005

    Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Am

2013
An Insight into the Roles of Dietary Tryptophan and Its Metabolites in Intestinal Inflammation and Inflammatory Bowel Disease.
    Molecular nutrition & food research, 2021, Volume: 65, Issue:5

    Topics: Colitis, Ulcerative; Gastrointestinal Microbiome; Humans; Indoles; Inflammatory Bowel Diseases; Kynu

2021

Trials

1 trial available for kynurenine and Colitis Gravis

ArticleYear
    Computational & theoretical chemistry, 2013, Feb-01, Volume: 1005

    Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Am

2013

Other Studies

6 other studies available for kynurenine and Colitis Gravis

ArticleYear
Serum Serotonin Differentiates Between Disease Activity States in Crohn's Patients.
    Inflammatory bowel diseases, 2020, 09-18, Volume: 26, Issue:10

    Topics: Adolescent; Adult; Biopsy; C-Reactive Protein; Colitis, Ulcerative; Colon; Crohn Disease; Cytokines;

2020
Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis.
    Inflammatory bowel diseases, 2018, 06-08, Volume: 24, Issue:7

    Topics: Adolescent; Adult; Aged; Biomarkers; Case-Control Studies; Chromatography, High Pressure Liquid; Col

2018
Ultrahigh-Performance Liquid Chromatography Tandem Mass Spectrometry with Electrospray Ionization Quantification of Tryptophan Metabolites and Markers of Gut Health in Serum and Plasma-Application to Clinical and Epidemiology Cohorts.
    Analytical chemistry, 2019, 04-16, Volume: 91, Issue:8

    Topics: Adult; Aged; Biomarkers; Chromatography, High Pressure Liquid; Citrulline; Cohort Studies; Colitis,

2019
IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.
    Gastroenterology, 2013, Volume: 145, Issue:2

    Topics: Animals; Azoxymethane; beta Catenin; Carcinogens; Cell Proliferation; Colitis; Colitis, Ulcerative;

2013
Bimodal plasma metabolomics strategy identifies novel inflammatory metabolites in inflammatory bowel diseases.
    Discovery medicine, 2014, Volume: 18, Issue:98

    Topics: Adult; Angiotensin II; Case-Control Studies; Colitis, Ulcerative; Crohn Disease; Female; G(M3) Gangl

2014
Levels of purine, kynurenine and lipid peroxidation products in patients with inflammatory bowel disease.
    Advances in experimental medicine and biology, 2003, Volume: 527

    Topics: Adenosine; Case-Control Studies; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Dise

2003